Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph not_applicable
3
30%
Ph phase_4
4
40%
Ph phase_3
2
20%

Phase Distribution

0

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
4(40.0%)
N/ANon-phased studies
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(1)
Other(3)

Detailed Status

Completed6
unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (10.0%)
Phase 32 (20.0%)
Phase 44 (40.0%)
N/A3 (30.0%)

Trials by Status

terminated110%
completed660%
unknown330%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_4

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

NCT04991350
completedphase_4

Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

NCT03690947
completedphase_4

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

NCT01922154
unknownphase_4

Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab

NCT03056092
completednot_applicable

Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

NCT03115255
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04991350Phase 4

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Terminated
NCT03690947Phase 4

Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

Completed
NCT01922154Phase 4

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Completed
NCT03056092Phase 4

Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab

Unknown
NCT03115255Not Applicable

Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

Completed
NCT01162746Phase 2

Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Completed
NCT02914626Phase 3

Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

Unknown
NCT01238393Not Applicable

Treatment of Epiretinal Membranes With Ranibizumab

Completed
NCT01626339Not Applicable

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Unknown
NCT00429962Phase 3

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10